The Law and Practice of Off-Label Prescribing and Physician Promotion

被引:20
作者
Syed, Shariful A. [1 ,2 ,3 ,4 ]
Dixson, Brigham A. [1 ,2 ,3 ,4 ]
Constantino, Eduardo [1 ,2 ,3 ,4 ]
Regan, Judith [1 ,2 ,3 ,4 ]
机构
[1] SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA
[2] SUNY Stony Brook, Dept Psychiat & Behav Sci, Psychiat, Stony Brook, NY 11794 USA
[3] CW Bill Young VA Med Ctr, Bay Pines, FL USA
[4] North Pursell & Ramos PLC, Nashville, TN USA
关键词
misbranded; approved use; intended use; physician promotion; law; pharmaceutical; DRUG-USE;
D O I
10.29158/JAAPL.200049-20
中图分类号
D9 [法律]; DF [法律];
学科分类号
0301 ;
摘要
Prescription of medications for off-label indications is an increasingly common practice; recent events highlight such prescribing as one of the cornerstones of evolving clinical treatment. Clinicians are afforded substantial deference in prescribing practices and other treatments falling within the realm of the actual practice of medicine, including prescribing for off-label indications. Yet clinicians are not necessarily free to promote a medication for the same off-label indication they may have just prescribed for a patient. While trends in jurisprudence appear to be favoring clinicians' freedom to promote prescription medication for any use, in a majority of jurisdictions, the U.S. government can still bring considerable weight to bear on clinicians promoting off-label uses of prescription medications. We review the relevant laws and regulations pertaining to off-label prescription and promotion, as well as the possible legal consequences. The regulations pertaining to physician and pharmaceutical manufacturers regarding off-label drug use are complex. Suggestions are provided to help physicians better navigate the medical-legal landscape when prescribing or promoting medications for off-label use. Physician mindfulness to pertinent legal precedents will allow them to prescribe and promote medications with a higher level of critical reasoning to optimize care and reduce risk.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [1] In Defense of Off-label Prescribing Reply
    Eguale, Tewodros
    Verma, Aman
    Tamblyn, Robyn
    JAMA INTERNAL MEDICINE, 2016, 176 (06) : 861 - 862
  • [2] Frequency of ill-founded off-label prescribing in Dutch general practice
    Gijsen, Ronald
    Jochemsen, Hadassa
    van Dijk, Liset
    Caspers, Peter
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (01) : 84 - 91
  • [3] Off-Label Prescribing and Polypharmacy Minimizing the Risks
    Leahy, Laura G.
    JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2017, 55 (02) : 17 - 22
  • [4] What Is "False or Misleading" Off-Label Promotion?
    Bi, Kathryn
    UNIVERSITY OF CHICAGO LAW REVIEW, 2015, 82 (02) : 975 - 1021
  • [5] Off-label prescribing patterns of antidepressants in children and adolescents
    Lee, Euni
    Teschemaker, Anna R.
    Johann-Liang, Rosemary
    Bazemore, Gina
    Yoon, Martin
    Shim, Kye-Sik
    Daniel, Marlon
    Pittman, Jerome
    Wutoh, Anthony K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (02) : 137 - 144
  • [6] From off-label prescribing towards a new FDA
    Tabarrok, Alex
    MEDICAL HYPOTHESES, 2009, 72 (01) : 11 - 13
  • [7] Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012
    Vilhelmsson, Andreas
    Davis, Courtney
    Mulinari, Shai
    PLOS MEDICINE, 2016, 13 (01):
  • [8] OFF-LABEL AND UNLICENSED PRESCRIBING IN HOSPITALIZED CHILDREN: PREVALENCE AND REASONS
    Man, Sorin Claudiu
    Primejdie, Daniela Petruta
    Sarkozi, Ingrid-Krisztina
    Popa, Adina
    FARMACIA, 2017, 65 (03) : 460 - 466
  • [9] Off-Label Prescribing: A Call for Heightened Professional and Government Oversight
    Dresser, Rebecca
    Frader, Joel
    JOURNAL OF LAW MEDICINE & ETHICS, 2009, 37 (03) : 476 - +
  • [10] Awareness, knowledge and views of off-label prescribing in children: a systematic review
    Balan, S.
    Hassali, M. A.
    Mak, V. S. L.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (06) : 1269 - 1280